Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesLand & ImprovementsLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pediatrix Medical (MD) Receivables (2016 - 2025)

Pediatrix Medical (MD) has disclosed Receivables for 17 consecutive years, with $229.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Receivables fell 20.39% to $229.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $229.7 million, a 20.39% decrease, with the full-year FY2025 number at $229.7 million, down 20.39% from a year prior.
  • Receivables was $229.7 million for Q4 2025 at Pediatrix Medical, down from $231.1 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $1.6 billion in Q4 2022 to a low of $229.7 million in Q4 2025.
  • A 5-year average of $708.5 million and a median of $306.0 million in 2022 define the central range for Receivables.
  • Peak YoY movement for Receivables: soared 429.9% in 2024, then tumbled 84.27% in 2025.
  • Pediatrix Medical's Receivables stood at $359.9 million in 2021, then surged by 345.49% to $1.6 billion in 2022, then fell by 11.9% to $1.4 billion in 2023, then crashed by 79.57% to $288.5 million in 2024, then dropped by 20.39% to $229.7 million in 2025.
  • Per Business Quant, the three most recent readings for MD's Receivables are $229.7 million (Q4 2025), $231.1 million (Q3 2025), and $239.0 million (Q2 2025).